A dose-ranging study of cefuroxime axetil in the treatment of lower respiratory tract infections in general practice.

Author: BrownG W, GriggsJ V, SpencerR C

Paper Details 
Original Abstract of the Article :
Cefuroxime axetil (CAE) is a prodrug of cefuroxime which is suitable for oral administration, being hydrolysed by non-specific esterases to release cefuroxime (CXM) into the bloodstream. This study was performed in four centres in the UK to investigate the efficacy and safety of CAE administered at ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/3582133

データ提供:米国国立医学図書館(NLM)

Cefuroxime Axetil: A Treatment for Lower Respiratory Tract Infections

Lower respiratory tract infections (LRTIs) are a common ailment, like a desert wind that can bring chills and discomfort. This research investigates the effectiveness of cefuroxime axetil (CAE) in treating community-acquired LRTIs. The study evaluated the efficacy and safety of CAE administered at two different dosages in general practice settings. The findings suggest that CAE is a safe and effective treatment option for LRTIs, with a high cure or improvement rate in both dosage groups.

A Desert Oasis for LRTIs

In this research, CAE emerges as a promising treatment for LRTIs, offering a high rate of cure or improvement. The study found that CAE was well-tolerated by patients, with minimal side effects. This suggests that CAE can provide a much-needed oasis of relief for individuals struggling with LRTIs, helping them navigate the discomfort and recover quickly.

Navigating the Desert of Infection

When battling an LRTI, finding the right treatment is crucial. This research indicates that CAE can be a valuable tool in the arsenal of healthcare professionals. By providing a safe and effective treatment option, CAE can help patients recover from LRTIs and return to their usual routines.

Dr. Camel's Conclusion

This research highlights the efficacy and safety of cefuroxime axetil in treating lower respiratory tract infections. The findings suggest that CAE can be a valuable treatment option for individuals seeking relief from these common ailments. Just as a traveler in the desert relies on a reliable compass for navigation, healthcare professionals can rely on CAE as a trusted guide in the treatment of LRTIs.

Date :
  1. Date Completed 1987-07-17
  2. Date Revised 2016-11-23
Further Info :

Pubmed ID

3582133

DOI: Digital Object Identifier

3582133

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.